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ABSTRACT 
After neuromuscular blockade is achieved in the surgical setting, it is important that the 
patient obtain adequate recovery. If the patient is extubated and sent to the post-anesthesia care 
unit without adequate recovery, there is a higher incidence of respiratory complications. Newer 
technology has made objective neuromuscular junction monitoring more available and affordable 
than in the past. The purpose of this Doctor of Nursing Practice (DNP) project was to develop a 
clinical practice guideline (CPG) to assist practitioners in monitoring residual paralysis. As a 
theoretical framework, Lewin’s Change Theory and the Knowledge to Action Framework was 
used to move current research into practice. Expert opinion was acquired to assist in the 
development of a CPG. The CPG was then appraised by four anesthesia providers to ensure that 
a high-quality CPG, ready for implementation, was developed. The CPG was appraised using the 
Appraisal of Guidelines for Research & Evaluation II (AGREE II) assessment platform. The 
results were clear that the CPG exceeded the 70% required to ensure a high-quality CPG with the 
scores for each domain ranging from 92% to 98%. All appraisers stated they would recommend 
the CPG for implementation into practice. 
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INTRODUCTION 
Background Knowledge 
Current Practice 
According to the United States Department of Health and Human Services, there are over 
40 million surgical procedures performed in the United States every year (Hall, Schwartzman, 
Zhang, & Liu, 2017). To provide a safe surgical field for the patient and the procedure, the 
anesthesia provider is often required to use medications to inhibit neuromuscular transmission to 
prevent movement during surgical manipulation. Once the procedure is complete, it is imperative 
for the anesthesia provider to assess the amount blockade present and ensure the patient has 
regained adequate neuromuscular function before moving the patient to the post-anesthesia care 
unit (PACU). When a typical monitor utilizing subjective data is used to monitor the level of 
paralysis, the incidence of residual paralysis is as high as 40% in patients entering the PACU 
(Brull et al., 2008). The lack of monitoring for residual paralysis can lead to serious respiratory 
complications, decreased patient satisfaction, postoperative pneumonia, and even death (Brull et 
al., 2008). In 2014, the average surgery in the United States costs $5,015. This cost goes up to 
$62,704 when there are postoperative respiratory complications. The American Association of 
Nurse Anesthetists (AANA) provides standards for practice which state “when neuromuscular 
blocking agents are administered, monitor neuromuscular response to assess the depth of block 
and degree of recovery” (American Association of Nurse Anesthetists, 2017). The physician 
anesthesia professional organization, the American Society of Anesthesiologists’ standards do 
not require the use of a neuromuscular monitor even in the presence of neuromuscular blockade 
(NMB) (American Society of Anesthesiologists, 2017). The two associations standards fall short 
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in providing a guideline for recommendations based on current evidence that supports using a 
train of four(TOF) ratio of >0.9 as the gold standard to ensure adequate recovery, using an 
objective measure to assess the TOF ratio, and excluding subjective measures that have been 
proven ineffective. (Plummer-Roberts, Trost, Collins, & Hewer, 2016).  
Definition of Terms 
Residual Paralysis 
After the anesthesia provider administers a neuromuscular blocking drug the patient 
becomes paralyzed to enhance the surgical field. When the paralytic is no longer needed, the 
patient receives a reversal drug to eliminate the paralysis. Complete reversal and readiness for 
extubation is determined by a TOF ratio of > 0.9 (Nagelhout, Neuromuscular blocking agents, 
reversal agents, and their monitoring, 2014). When this number is not achieved, the patient is 
said to have residual paralysis.  
Train-of-Four Ratio 
Using a nerve stimulator, the anesthesia provider delivers four separate stimuli every 0.5 
seconds and a frequency of 2 Hz. A comparison is then made regarding the size of the fourth 
twitch to the size of the first twitch (Nagelhout, Neuromuscular blocking agents, reversal agents, 
and their monitoring, 2014). The TOF ratio is equal to the size of the fourth twitch divided by the 
size of the first twitch. The TOF ratio falls within range of 0.9 and 1.0, and the implications of 
these ratios are described in further detail below.  
Objective Monitoring 
Quantitative monitoring that displays a TOF ratio where the stimulator is coupled with a 
transducer and a number value is displayed. 
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Significance 
The Neuromuscular Junction 
The neuromuscular junction plays an important role in how neuromuscular blocking 
drugs allow for improved airway access and operative field optimization during surgery. 
Acetylcholine (ACh) is the neurotransmitter that is released from the presynaptic cleft and binds 
to the nicotinic cholinergic receptor on the motor end plate which opens an ion channel allowing 
for potassium to exit while sodium and calcium enter (Butterworth, Mackey, & Wasnick, 2013). 
This movement of ion creates an action potential along the muscle membrane, which results in a 
muscle contraction. Neuromuscular blocking medications will inhibit this action affording 
muscle relaxation when needed. In order for patients to recover from these drugs, it is important 
to measure the degree of relaxation and administer an antidote to reverse the relaxation.  
Monitoring Neuromuscular Blockade 
According to the American Association for Nurse Anesthetists (AANA), the standard of 
care is to monitor neuromuscular response when utilizing a NMB drug (American Association of 
Nurse Anesthetists, 2017). It does not state how often it should be measured, what kind of device 
to use, what measurement determines safety to reverse, or what measurement means it is safe to 
remove the endotracheal tube. In many operating rooms, only subjective, either visual or tactile, 
evaluations determine if adequate reversal has taken place and it is safe to extubate (Brull & 
Kopman, 2017). Several studies have concluded that the only method to accurately determine if 
adequate reversal has taken place and it is safe to extubate is by using an objective measuring 
device that reveals a train-of-four ratio (TOF) of greater than 0.9 measured at the adductor 
pollicis via the ulnar nerve (Brull & Kopman, 2017). For this reason, the absence of this 
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recommendation in either of the current professional standards for monitoring falls short in 
protecting patients from residual neuromuscular blockade. 
As stated above, the TOF ratio of >0.9 is the only reliable measure to determine if 
adequate reversal has occurred. To obtain the ratio a peripheral nerve stimulator must be used to 
deliver four electrical stimuli of 2 Hertz every 5 seconds. The TOF ratio can be calculated by 
comparing the first twitch to the fourth twitch (Figure 1). If the fourth twitch is half of the first, 
the TOF ratio is 0.5. At a ratio of 0.5 the patient can lift their head for 5 seconds, but cannot 
adequately protect their airway. Even at a TOF ratio of 0.8 there is still risk for impaired 
swallowing and aspiration risk (Hammermeister, Bronsert, Richman, & Henderson, 2016). 
Research has shown that subjective measures to obtain a TOF ratio cannot determine the 
difference between a TOF ratio of 0.4 and 0.9 and that only objective measures can adequately 
determine adequate reversal (Viby-Mogensen et al., 1985). Research has also shown that 
commonly taught subjective measures such as grip strength, head lift, and adequate tidal volume 
are not reliable in detecting residual blockade (Brull & Kopman, 2017).  
 
FIGURE 1. Train-of-four ratios. (Hammermeister, Bronsert, Richman, & Henderson, 2016) 
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The site of monitoring is also an important factor when determining the amount of 
residual blockade. The preferred site to monitor muscle contraction from the nerve stimulator is 
by placing two electrodes over the ulnar nerve (Nagelhout, Neuromuscular blocking agents, 
reversal agents, and their monitoring, 2014) (Figure 2). When stimulation from the nerve 
stimulator is delivered to the electrodes, adduction of the thumb can be visualized to determine 
the TOF ratio. One problem with this site is that is often out of reach to the anesthesia provider 
or under the sterile drape. In this situation, the facial nerve is often evaluated and twitches are 
evaluated by eyelid movement. Due to distribution and blood flow, the eyelid is best to 
determine the onset of the drug. However, this is not true for the recovery where the ulnar nerve 
correlates to recovery of the diaphragm (Nagelhout, Neuromuscular blocking agents, reversal 
agents, and their monitoring, 2014). This is another reason why simple subjective measures are 
not adequate to assess recovery.  
 
a) Facial Nerve     b) Ulnar Nerve 
FIGURE 2. Neuromuscular monitoring sites. (Nagelhout, Neuromuscular Blocking Agents, Reversal 
Agents, and their Monitoring., 2014) 
   
16 
The most common peripheral nerve stimulator used is a hand-held device that has two 
electrodes, that are placed on the nerve to create contraction. The two muscles used to assess 
TOF ratio are the adductor pollicis via the ulnar nerve and the orbicularis oculi via the temporal 
branch of the facial nerve. The TOF button is set to deliver 50 Hz of current and eyelid 
movement is observed to assess the ratio. The facial nerve is the most common site because the 
anesthesia provider usually has easy access to the patient’s face. However, this indicator only 
provides the provider with unreliable subjective data. Multiple objective nerve stimulators 
provide an actual reading of TOF ratio that take clinician error out of the equation. The gold 
standard is mechanomyography (MMG), however, this is a very cumbersome device and not 
practical in every clinical setting (Plummer-Roberts, Trost, Collins, & Hewer, 2016). Another is 
an objective measure that is accurate and practical is acceleromyography (AMG) (Figure 3). The 
AMG will be used as a reference for this paper based on its accuracy and availability. When 
patients enter the post-anesthesia care unit (PACU) after using the AMG only 4% of them have a 
TOF ratio of <0.9. When the subjective monitor is used, the incidence of residual paralysis is as 
high as 40% in patients entering the PACU (Brull et al., 2008). The ulnar nerve is the easiest and 
most accurate way to assess a TOF ratio and determine if the patient will not have residual 
paralysis. There are procedures when the arms are tucked and there is no access to the ulnar 
nerve. In this situation, the accelerometer may be placed on the face using double sided tape to 
monitor twitches from the facial nerve. 
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FIGURE 3. STIMPOD NMS450 acceleromyography on the ulnar nerve. (Ortega et al., 2018) 
Reversal of neuromuscular blockade. Once a procedure is completed and there is no 
longer a need for NMB, the anesthesia provider has the option to give a classification of 
neuromuscular junction reversal drugs known as acetylcholinesterase inhibitors. When these 
drugs enter the synapse, they bind to the acetylcholinesterase receptors, which prevent the 
breakdown of ACh (Nagelhout, Neuromuscular blocking agents, reversal agents, and their 
monitoring, 2014). This action increases the amount of ACh around the junction. This increases 
the amount of ACh that competes with the NMB to bind to the nicotinic receptor, therefore 
allowing the muscle to contract again. Depending on the chosen reversal drug, the number of 
twitches should be monitored to guide the correct dosage. Even when the appropriate number of 
twitches are obtained and the patient is reversed, it can still take up to 20 minutes for the TOF 
ratio to be >0.9 (Nagelhout, Neuromuscular blocking agents, reversal agents, and their 
monitoring, 2014). It is also important to note there are side effects of giving an 
acetylcholinesterase inhibitor including bradycardia, arrhythmias, hypotension, diarrhea, 
bronchoconstriction, and post-operative nausea and vomiting (Naguib, 2015).  
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Another reversal drug that is new to the market is Sugammadex. This is the first reversal 
drug that does not affect ACh so it does not seem to have the negative effects described earlier. 
Another advantage is that Sugammadex can be given at a higher dose to reverse even a profound 
block within 3 minutes (Naguib, 2015). Some of the noted limitations include procedural 
hypotension, recurrence of the block, inability to reverse benzylisoquinolinium neuromuscular 
blockers, and most notably allergic reactions (Naguib, 2015). Although this drug is showing 
promising results for reversing certain NMB medications, studies are showing that objective 
TOF measurements are still necessary to adequately dose Sugammadex to assure adequate 
reversal while minimizing the adverse effects associated with the drug (Kaufhold et al., 2016).  
Residual Paralysis 
In the past, a TOF ratio of 0.7 was the gold standard for determining if residual paralysis 
was present and would lead to complications (Viby-Mogensen et al., 1985). With new research 
into the side effects and negative outcomes associated with residual paralysis, the new standard 
is a TOF ratio of 0.9. In fact, the definition of residual paralysis is “a train-of-four ratio (TOFR) 
<0.9 at the adductor pollicis.” (Donati, 2013) This was updated based on evidence that a TOF of 
0.9 was necessary to ensure recovery of laryngeal function including the ability to swallow and 
airway protection. Another important physiologic factor is that when the TOF ratio is <0.9 the 
hypoxic drive can still be impaired (Donati, 2013). This is important in patients with lung disease 
who use oxygen chemoreceptors to regulate the respiratory cycle. 
When subjective peripheral nerve stimulators are used to assess TOF ratio, the number of 
patients arriving in the PACU with a residual neuromuscular block in effect is reported to be as 
high as 40% (Brull & Kopman, 2017). This number can be greatly reduced to approximately 4% 
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when using objective measures to verify a TOF ratio of >0.9 before extubation (Brull et al., 
2008). There is also research suggesting that duration of action of NMB drugs as cited by the 
manufacturer is not accurate and can far exceed the stated duration of action. This finding is due 
to factors that can prolong paralysis, including drug interaction, antibiotics, electrolyte 
abnormalities, and other pathophysiologic factors that can affect the duration of action 
(Nagelhout, Neuromuscular blocking agents, reversal agents, and their monitoring, 2014). Due to 
these many factors, the anesthesia governing boards in other countries have already updated their 
standard monitoring protocol. These protocols include language describing the recovery process 
and how to monitor it more effectively. In 2015, the Association of Anesthetists of Great Britain 
and Ireland added addendum #3 to their standards. These standards outline a peripheral nerve 
stimulator is mandatory to assess NMB, the device should be used throughout the perioperative 
process, return of motor function is a TOF ratio of 0.9, and most importantly a quantitative nerve 
stimulator is required to ensure a TOF ratio of 0.9 (Checketts M. et al., 2015). 
Complications from residual paralysis. Although there are several complications that 
can arise when a patient is extubated with residual paralysis, defined as a TOF <0.9, the most 
common and dangerous effect is that on the respiratory system. Common complications include 
respiratory failure, upper airway collapse, inability to swallow, re-intubation, and hypoxia 
(Plaud, Debaene, Donati, & Marty, 2010). The evidence shows that there is a much higher 
percentage of critical respiratory events when the patient arrives in the PACU with a TOF ratio 
of <0.9. When there is noted residual paralysis, there is also a higher incidence of postoperative 
pneumonia (Farhan, Moreno-Duarte, Mclean, & Eikermann, 2014). 
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Although respiratory complications are the greatest concern, other complications are also 
common. Patients undergoing ambulatory surgery are often required to walk shortly after 
surgery. In a patient with residual paralysis, muscle weakness can affect their ability to ambulate 
and lead to an increased risk of falling (Farhan, Moreno-Duarte, Mclean, & Eikermann, 2014). 
There is also evidence suggesting the use of an AMG improves the patients’ perception of their 
recovery and therefore their patient satisfaction scores are more positive then when using 
subjective measure (Plummer-Roberts, Trost, Collins, & Hewer, 2016). Both measures are 
directly tied to reimbursement for the provider and can affect the amount billed and received 
after performing the procedure. Another issue related to costs and residual paralysis is that when 
patients arrive in the PACU with a TOF of <0.9 their discharge times are significantly longer 
than those without a residual blockade. In the United States, the average costs for a surgery is 
$5,015, when there are postoperative respiratory complications that number rises to $62,704 
(Farhan, Moreno-Duarte, Mclean, & Eikermann, 2014).  
Problem Statement 
There is a wide variety of methods anesthesia providers use to assess the degree of NMB 
present in surgical patients in the United States. While the evidence provided shows that up to 
40% of patients arriving in the PACU have a TOF ratio of < 0.9, surveys have found that many 
current anesthesia practitioners believe that this number is less than 1% (Brull & Kopman, 2017). 
One way to make the measurement of neuromuscular blockade more objective is using a 
monitoring device that quantitatively measures the TOF ratio. In other countries, anesthesia 
governing boards have adopted standards which include the use of TOF ratio and objective 
monitors. However, two U.S. professional anesthesia associations, American Society of 
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Anesthesia and American Association of Nurse Anesthetists, have not updated their standards to 
incorporate this new monitoring technology to improve patient safety. As a result of not using an 
AMG, patients face a higher risk of developing postoperative complications which can be 
detrimental and costly to the patient, provider, and facility.  
Study Purpose 
The purpose of this project was to use information gathered by expert clinical providers 
to create a CPG and then evaluate a new CPG for a local anesthesia group via a systematic 
process. The intent was to develop a local CPG whereby residual neuromuscular blockade is 
prevented by assuring a TOF ratio of > 0.9 is achieved on all patients receiving NMB 
medications. This project aimed to gather data about current practice habits, attitudes, and beliefs 
regarding neuromuscular blockade management via personal interviews with expert anesthesia 
personnel who assisted in the guideline development and evaluation. This project aimed to 
answer the following question: At this anesthesia group, will the development of a CPG with 
input by facility stakeholders lead to the formulation of a high scoring CPG regarding the 
management of NMB as determined by the AGREE II tool?  
THEORETICAL FRAMEWORK 
Lewin’s Change Theory 
Healthcare facilities and organizations have policies and behaviors that are specific to 
each one of them. Many of these policies are out of date and do not reflect current evidence. It is 
estimated that up to 45% of patients are receiving care that does not correspond with current 
evidence (Graham I. et al., 2006). Kurt Lewin’s theory strives to understand and define the 
behaviors that the facilities, and the stakeholders, have and developed a way to try and 
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constructively break them down to promote new change. The model defined two forces that are 
in constant movement with each other; which is why the theory is also called Lewin’s force field 
analysis. The first force is called the restraining forces that include factors that oppose change 
and make it more difficult. The competing force is called the driving forces. These include 
components that help to drive the change (Sutherland, Applying Lewin's change management 
theory to the implementation of bar-coded medication administration, 2013). 
Lewin broke down the process of change into three phases that include the unfreezing 
stage, the change stage, and the refreezing stage. In the first stage, the problems are identified 
and the involvement of the stakeholders will begin. In this phase, there is resistance as current 
practice and norms are challenged. In the operating room, as evidence has shown, the current 
practice regarding NMB monitoring is outdated and needs to be revised. However, many of the 
current anesthesia providers still rely on, and are comfortable with, this practice. Barriers to this 
project in this phase included breaking down these norms and overcoming the resistance to 
change. In this phase, barriers were discussed before moving to the next step of change. 
The second step in the change theory is the actual change implementation. Several 
stakeholders including anesthesia providers, managers, and educators were part of the 
development of the CPG. In this phase, the CPG was presented to the stakeholders so they 
understood the CPG and the benefits it would provide to their patients. There needed to be 
involvement from all users and available equipment necessary to assess TOF ratio needed to be 
present. A project leader was identified at the facility to help ensure the CPG was understood and 
is successfully implemented. 
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The third and final step in Lewin’s theory was the refreezing stage. After the CPG was 
presented to the facility, the third phase was to make it part of the standard of care on the given 
unit. This took take place after all barriers and problems were resolved and stakeholders agreed 
that this will provide the quality of care they strive to provide for their patients. For this CPG to 
successfully become part of the standard of care, the facility will need ongoing support from the 
leader who will ensure that necessary education and equipment is always available to those who 
need it.  
Knowledge to Action Framework 
Lewin’s change theory helps to identify barriers and actions that can effect change. The 
Knowledge to Action (KTA) framework is designed to translate current literature and CPG’s into 
practice as fast as possible. Graham identified in research that 45% of patients are not receiving 
correct care, 25% of care is being given that is not needed, and outcomes could be improved by 
up to 30% if up to date research was incorporated into practice (Graham I. et al., 2006). To 
overcome this Graham and colleagues developed the knowledge to action process that 
incorporated what they describe as the knowledge funnel and the action cycle (Figure 4).  
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FIGURE 4. Knowledge to action process. (Graham I. et al., 2006) 
The knowledge funnel is where knowledge creation happens and is transitioned to a 
presentable form for the given stakeholders. The first stage is known as knowledge inquiry and is 
where an unmanageable amount of knowledge, ideas, studies, and questions exist. It is where 
knowledge inquiry begins before true literature review is performed. Moving down the 
knowledge funnel is the knowledge synthesis section. In this stage, a literature review is 
performed to ensure up to date evidenced-based research supports the initial inquiry. This stage 
will include studies, systematic reviews, and meta-analysis if available (Graham I. et al., 2006). 
In the final stage of the knowledge funnel knowledge tools such as CPG’s are either adopted or 
developed to provide a clear and concise recommendation for the stakeholders. This is where the 
CPG outlining reversal of NMB was established before moving on to the action and 
implementation stage. 
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Once the CPG was developed and supported by evidence, it moved into the action cycle 
of the KTA process. Parts of the KTA model that were used to operationalize this project were 
the steps in the KTA process used to identify and adapt knowledge at a local level, assess 
barriers, and then select and tailor knowledge which may facilitate implementation. One 
anesthesia provider was identified and interviewed to evaluate current provider practice 
regarding neuromuscular reversal and assess the applicability of a locally created CPG. Moving 
through the cycle, the next step of this project was to work with the anesthesia provider 
champion to identify any barriers that are present at the facility and use this information to tailor 
the CPG to this facility. Some expected barriers include the cost of purchasing objective TOF 
monitors, availability of monitors, and change in habits and norms. Upon completion of these 
steps, a local CPG for implementation was created. An aim was to evaluate the utilization of the 
CPG among the anesthesia practitioners and if the CPG was adopted as a standard of care for the 
facility.  
SYNTHESIS OF EVIDENCE 
Before beginning to develop a CPG that will provide guidance on when to reverse 
paralysis and what is the best method, an extensive literature review was completed to find the 
best evidence to support the need for change. There were three primary literature searches; 
including PubMed, Cumulative Index of Nursing and Allied Health Literature (CINAHL), and 
the Cochrane Library. The primary keywords used were peripheral nerve stimulation and 
residual neuromuscular block. Other related terms included objective monitoring, neuromuscular 
junction, anesthesia, and subjective monitoring. Inclusion criteria for the literature review 
included studies published within the last ten years, human subjects, English language, and full-
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text availability. The searches yielded 27 results, 4 results, and 5 results respectively for a total of 
36 primary results. Using the other defined keywords yielded several other studies used to 
support the evidence. For this project, ten studies met the criteria for further synthesis of 
evidence (Table 1).  
A large systematic review, completed in 2008, determined the benefit of using an 
objective monitor when evaluating the ability to detect residual paralysis compared to using 
subjective monitoring. In this review, 38 studies met the inclusion criteria and thus utilized as 
evidence (Claudius & Viby-Mogensen, 2008). The study looked at four groups, each with 
different studies included and different levels of evidence, to determine the benefit of using 
objective monitoring. After careful review, it determined that there is strong evidence to support 
perioperative monitoring with an objective monitor to detect residual paralysis. The study also 
compared the standard monitoring methods to objective monitoring and determined that using 
tools such as an acceleromyography is more sensitive than tactile evaluation and will determine 
the correct TOF ratio of 0.9 over 90% of the time compared to only 60% with conventional 
methods (Claudius & Viby-Mogensen, 2008). 
Fortier et al. (2015) performed the RECITE study to determine the severity of residual 
neuromuscular blockade with current practice. The study aimed to determine the number of 
patients entering the PACU with a TOF ratio of less than the recommended 0.9 to prevent 
respiratory events. The study took place at eight hospitals in Canada and included three hundred 
and eight participants. Rocuronium, a non-depolarizing neuromuscular blocking drug, was used 
and then was reversed with Neostigmine. The results showed a very high rate of residual NMB at 
63% (95% CI) at extubation, and 56% (95% CI) at arrival to the PACU (Fortier et al., 2015). It 
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also determined that the incidence of residual paralysis did not differ among all different 
populations including gender, age, body mass index (BMI), or type of surgery. This study 
concluded that residual paralysis is common in all patients, and in all surgeries, and recommends 
changing current practice to using a more advanced monitoring system to detect residual 
paralysis. 
In two randomized control trials, the evidence supported the use of an objective measure 
such as acceleromyography to determine a TOF ratio of >0.9. Murphy et al. (2011) determined 
that when using the objective measure, the group had a significantly lower incidence of residual 
blockade compared to the control group. In a similar study, the use of an objective monitor was 
associated with a lower incidence of a residual blockade of only 3% compared to the control 
group in which 16.7% of them entered the PACU with TOF ratio of <0.9 (Gatke, Viby-
Mogensen, Rosenstock, Jensen, & Skovgaard, 2002) 
 
   
28 
TABLE 1. Synthesis of evidence. 
Author/ Year Purpose Design Sample Data Collection/Results Findings 
Cedborg et al. (2014).  
 
Pharyngeal function and 
breathing pattern during 
partial neuromuscular 
block in the elderly. 
Evaluate the effects of 
NMB on individuals 
older than 65. 
Pharyngeal function, 
coordination of 
breathing and 
swallowing, and airway 
protection were 
assessed. 
Non-randomized 
control.  
TOF ratio assessed at 
0.7, 0.8, and 0.9 
N=23 
 
Study group: 17 
 
Control Group: 6 
Swallowing and 
pharyngeal dysfunction 
-Control 37% 
-Study 71% (P=0.005) 
No significant difference 
in control and study after 
TOF ratio of >0.9 
(P=0.31)  
 
Coordination of breathing 
and swallowing 
No significant difference 
in control and study group 
(P=0.08) 
 
 Mechanical properties 
and timing of pharyngeal 
swallowing and 
swallowing apnea 
No significant difference 
between control and 
study.  
Pharyngeal phase was 
shorter in men compared 
to women (P=0.013, 
ANOVA) 
 
Resting upper esophageal 
sphincter (UES) pressures 
Significantly decreased 
with partial block (TOF 
0.70, P < 0.001; 0.80, P < 
0.001; and >0.90, P = 
0.007) 
Increased pharyngeal 
dysfunction exists in 
those >65 years old when 
NMB exists.  
 
This leads to increased 
risk on aspiration and 
extended hospital stay. 
 
Resting esophageal 
sphincter tone is 
decreased with residual 
blockade 
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TABLE 1 – Continued  
Author/ Year Purpose Design Sample Data Collection/Results Findings 
Checketts et al., 2016.  
 
Recommendations for 
standards of monitoring 
during anesthesia and 
recovery 2015: 
Association of 
Anesthetists of Great 
Britain and Ireland 
Recommendations for 
the standard of care for 
the Association of 
Anesthetists of Great 
Britain and Ireland 
Guideline for 
standard of care 
Appendix 3: 
monitoring of 
neuromuscular 
blockade during 
induction, 
maintenance, and 
recovery of anesthesia 
Updates and replaces 
4th edition of standard 
of care 
 Recommendations 
-PNS mandatory when 
patients receive NMB 
drugs 
 
-TOF ratio of 0.9 most 
reliable for safe reversal 
 
-quantitative PNS is 
required to accurately 
assess TOF ratio. 
 
Claudius & Viby-
Mogensen, 2008. 
 
Acceleromyography for 
Use in Scientific and 
Clinical Practice 
Evaluate current 
evidence and the 
relationship between 
using an 
acceleromyography 
monitor to access 
residual neuromuscular 
block (TOF ratio <0.9)  
Systematic review.  Group 1: Use of 
acceleromyography 
for establishing dose-
response relations. 3 
 
Group 2: 
Acceleromyography 
compared with 
mechanomyography in 
pharmacodynamics 
studies. 13 
 
Group 3: 
Acceleromyography 
compared with 
electromyography. 6 
 
Group 4: Clinical 
studies comparing 
acceleromyography to 
signs, symptoms, and 
tests of residual 
paralysis. 16 
Group 1: insufficient 
evidence due to the 
validity of studies. 
 
Group 2: Grade C 
evidence supporting use 
of the acceleromyography 
to access onset time and 
recovery using TOF ratio.  
 
Group 3: Grade C 
evidence supporting use 
of the acceleromyography 
interchangeably with 
electromyography to 
assess TOF ratio 
 
Group 4: Grade A 
evidence that 
acceleromyography is 
more sensitive to  
There is strong evidence 
that supports 
perioperative monitoring 
with an objective monitor 
(acceleromyography) to 
detect residual paralysis.  
 
Acceleromyography is 
more sensitive than any 
of the usually applied 
tests including subjective 
or tactile evaluation.  
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TABLE 1 – Continued  
Author/ Year Purpose Design Sample Data Collection/Results Findings 
    assessing residual 
paralysis than usual 
applied tests (subjective). 
Also improves detection 
of residual paralysis. 
 
 
Debaene, Plaud, Dilly, & 
Donati, 2003. 
 
Residual Paralysis in the 
PACU after a Single 
Intubating Dose of 
Nondepolarizing Muscle 
Relaxant with an 
Intermediate Duration of 
Action.  
Determine the amount 
of residual paralysis in 
the PACU after 
receiving a single dose 
of a non-depolarizing 
drug during intubation.  
Over an 8-month 
period in one facility 
in France 
 
Prospective, open-
labeled, 
nonrandomized, 
observational study 
N=526 
 
ASA I-III 
 
No reversal agent was 
given 
 
On arrival to the 
PACU, the TOF ratio 
was assessed using 
objective measures.  
85 (16%) had a TOF of 
<0.7. 237 (45%) had a 
TOF of < 0.9. (P=0.01)  
 
When checked at two 
hours after drug TOF 
ratio of <0.9 was present 
in 37% 
 
When TOF ratio of <0.9 
was achieved head lift test 
and tongue depressor test 
failed in 15% of patients.  
 
The incidence of residual 
paralysis is clinically 
significant even two 
hours after the drug is 
given.  
 
Reversal should always 
be used when objective 
measures are not 
available.  
  
 
Drobnik et al., 2010. 
 
A randomized 
simultaneous comparison 
of acceleromyography 
with a peripheral nerve 
stimulator for assessing 
reversal of Rocuronium-
induced neuromuscular 
blockade with 
Sugammadex. 
Determine the 
relationship between 
acceleromyography and 
PNS measuring reversal 
after Sugammadex 
Assessor blinded, 
randomized, parallel 
group.  
N=91 
Randomized at 4 
facilities. 
 
Acceleromyography 
was measured on one 
arm and PNS on the 
other.  
 
30 were given 1mg 
-28 completed study 
 
61 were given 4mg 
-61 completed  
Scatter plot used to 
document times and then 
compared each group.  
 
Group given 1mg took 
significantly longer (2.3-
148min, mean 17.2, SD 
28.6, CI 95%)  
 
Group given 4mg (0.6-
3.2min, mean 1.5 SD 0.7, 
CI 95%) 
 
While Sugammadex 
substantially reduces the 
amount of time to reach a 
TOF ratio of 0.9, using 
an acceleromyography 
monitor is still needed to 
ensure adequate reversal.  
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TABLE 1 – Continued  
Author/ Year Purpose Design Sample Data Collection/Results Findings 
    PNS range in min (0.03-
1.7, mean 0.8 SD 0.3, CI 
95%) 
 
Acceleromyography 
range in min (0.6-3.2. 
mean 2.1 SD 1.7, CI 
95%) 
 
 
Fortier et al., 2015 
 
The RECITE Study: A 
Canadian Prospective, 
Multicenter Study of the 
Incidence and Severity of 
Residual Neuromuscular 
Blockade 
To study and determine 
the incidence of residual 
NMB (TOF <0.9) just 
before extubation. 
 
8 hospitals in Canada 
Prospective 
observational study 
 
TOF ratios were 
obtained immediately 
at PACU using 
acceleromyography 
 
Anesthesia providers 
used subjective 
measures to assess 
TOF ratio before 
extubation.  
 
IRB approved and 
consent was obtained.  
 
N=302 
 
Mean age 48 
 
70% female 
 
54% ASA II 
 
 
Incidence of residual 
blockade at extubation 
was 63.5% (95% CI) and 
56.5% (95% CI) at arrival 
to PACU.  
 
Use of qualitative PNS 
was associated with a 
lower residual blockade 
on arrival in PACU. 
51.1% vs 67.1%. 
(P=0.028) 
 
Each increase in TOF 
ratio of 0.1 was associated 
with 4% fewer bed visits 
in PACU (P=0.013) 
 
Incidence of residual 
blockade (TOF<0.9) was 
63.5% (95% CI)  
 
There is no difference in 
residual blockade 
between age or ASA 
class.  
 
Lower the TOF ratio the 
more likely to need 
supplemental oxygen.  
Gatke, Viby-Mogensen, 
Rosenstock, Jensen, & 
Skovgaard, 2002. 
 
Postoperative muscle 
paralysis after 
Rocuronium: less  
Determine if using an 
acceleromyography tool 
is more effective in 
assessing residual 
paralysis than not using 
a PNS.  
Randomized control 
study 
IRB approved.  
 
N=120 
 
TOF group (n=60) 
 
Control group (n=60) 
Study group: 
Residual paralysis (TOF 
<0.8) was found in 3% 
(P=0.029) 
 
Control Group: 
 
Use of 
acceleromyography is 
associated with lower 
incidence of a residual 
blockade and increased 
time in recovery.  
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TABLE 1 – Continued  
Author/ Year Purpose Design Sample Data Collection/Results Findings 
residual block when 
acceleromyography is 
used.  
 
   Residual paralysis was 
found in 16.7% (P=0.029) 
 
 
Murphy et al., 2008. 
 
Intraoperative 
Acceleromyographic 
Monitoring Reduces the 
Risk of Residual 
Neuromuscular Blockade 
and Adverse Respiratory 
Events in the Post 
Anesthesia Care Unit. 
Compare the use of 
objective monitoring 
and subjective 
monitoring when 
assessing for residual 
NMB.  
Randomized control 
study 
N=185 
Group 1: Monitored 
using 
acceleromyography  
 
Group 2: Monitored 
using conventional 
subjective measures.  
Patients undergoing 
surgery that need to 
have NMB drugs 
during the procedure.  
 
The study was IRB 
approved and consent 
was obtained.  
Conventional TOF group 
arriving to PACU 
With residual blockade 
<0.9TOF 
30% (P=0.0001) 
13% arriving in the 
PACU with severe 
blockade of <0.7 TOF 
ratio (P=0.001) 
Median SpO2 value 95% 
arriving in PACU 
(P=0.0001) 
 
Acceleromyography 
group 
4.5% arriving to PACU 
with <0.9 TOF ratio 
(P=0.0001) 
0% arriving to PACU 
with TOF <0.7 (P=0.001) 
Median SpO2 value 
arriving to PACU 97% 
(P=0.0001) 
 
Severe hypoxia was seen 
in 21.1% of control group 
and 0% of the study group 
(P=0.0001) 
 
There is a significant 
difference in the two 
groups and TOF ratio. 
The acceleromyography 
group had a significantly 
lower number of residual 
paralysis than the 
subjective group.  
 
Acceleromyography can 
significantly reduce the 
risk of adverse 
respiratory events.  
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Author/ Year Purpose Design Sample Data Collection/Results Findings 
Murphy et al., 2011. 
 
Intraoperative 
Acceleromyography 
Monitoring Reduces 
Symptoms of Muscle 
Weakness and Improves 
Quality of Recovery in the 
Early Postoperative Period 
Determine if using an 
acceleromyography monitor 
during the perioperative 
period will reduce symptoms 
of muscle weakness and 
improve the quality of 
recovery compared to the use 
of a subjective tool.  
Randomized 
control study  
 
Single 
hospital in 
Chicago 
 
IRB approved 
 
N= 155 
 
Acceleromyography 
group monitored 
during perioperative 
phase. 76 
 
Control group 
monitored during 
perioperative phase 
with subjective 
measures. 74 
TOF ratio on admission to 
PACU was significantly higher 
in the acceleromyography 
group (0.98) than in the control 
group (0.88) (P=0.004) 
 
Patients with TOF <0.9 was 
14.5% vs. 50% (P=0.0001) 
 
Patients with TOF <0.7 was 4% 
vs 18.9% (P=0.0004) 
 
The linear model revealed 
study group had less overall 
weakness and fewer symptoms 
including muscle weakness 
across all points measured 
(P=0.0001) Median rating was 
4 in the study group compared 
to 6 in control group using 1-10 
scale 
 
Patients in the 
acceleromyography 
group had a lower 
incidence of TOF ratio 
<0.9 entering the 
PACU 
 
Patients also exhibited 
fewer signs of muscle 
weakness.  
Sauer, Stahn, Soltesz, 
Noeldge-Schomburg, & 
Mencke, 2011. 
 
The influence of residual 
neuromuscular block on 
the incidence of critical 
respiratory events. A 
randomized, prospective, 
placebo-controlled trial.  
Determine the correlation 
between residual NMB and 
critical respiratory events 
Randomized 
placebo-
controlled 
clinical trial 
N=114 
 
Group 1: patients 
given neostigmine 
(20mcg/kg) 
 
Group 2: placebo 
group.  
 
Group 1: 16 patients became 
hypoxic in PACU (SaO2<93%) 
All patients were extubated 
with a TOF ratio >0.9 
(P=0.021) 
 
Group 2 29 patients became 
hypoxic in PACU. (P=0.021) 
Median TOF ratio on 
extubation was 0.7. (P=0.0001) 
Even minimal residual 
blockade is associated 
with critical 
respiratory events 
including hypoxemia 
in the PACU. 
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Other studies included the effects of even a minimal amount of residual block and the 
resulting associated complications. The highest risk determined is that the patients become 
hypoxic due to inability to protect their airway. The authors found that in the hypoxic group, 
45% of them had a TOF ratio of <0.9 (Sauer, Stahn, Soltesz, Noeldge-Schomburg, & Mencke, 
2011). Studies also showed the incidence of residual blockade based on the timing of the NMB 
drug and how long the effects can last. The study concluded that when the residual blockade was 
checked two hours after giving a NMB drug, 37% of the patients still had a TOF ratio of <0.9 
determining that a reversal agent should always be used after given a NMB drug (Debaene, 
Plaud, Dilly, & Donati, 2003). 
After completing a thorough literature review examining the current practice and 
consequences of residual blockade, the current evidence overwhelmingly supports the need to 
update practice and include the use of objective tools after a patient is given a NMB drug. While 
a few of the studies are older than ten years, these are still relevant in current practice. Many of 
these studies are being used to develop similar clinical practice guidelines within the anesthesia 
community. The research presented provides insight into the problem of residual neuromuscular 
blockade, along with identifying the lack of consistent practice and the negative outcomes 
associated with an inadequate reversal. Highlighting the significant gap between the research and 
practice, in February of 2018, the Anesthesia Patient Safety Foundation created a collaborative 
panel on neuromuscular blockade and patient safety and presented recommendations from the 
panel. These recommendations include quantitative monitoring when NMB drugs are used, 
peripheral nerve stimulators should be mandatory, clinical signs should not be used to assess 
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adequate recovery, and organizations need to develop standards and guidelines (Murphy G., 
2018). 
METHODS 
Design 
This project aimed to change current practice using Lewin’s change theory by unfreezing 
the current practice of not using a CPG to prevent the complication of a residual neuromuscular 
blockade. The next step was to change the management of neuromuscular blockade by 
developing a CPG with stakeholders input for use at the local level. Lastly, the goal was to re-
freeze the new practice by creating a CPG for implementation at this facility as standard practice 
(Sutherland, Applying Lewin's Change Management Theory to the Implementation of Bar-
Coded Medication Administration, 2013). The project used elements of the knowledge to action 
framework to translate the current research into a CPG at this local facility (Graham I. D. et al., 
2006). After the CPG was completed it was evaluated by anesthesia providers trained to use the 
AGREE II tool to assess quality (Brouwers et al., 2010). After the CPG was determined to be 
valid, the CPG was presented to the local anesthesia department.  
Setting 
This project took place within an anesthesia practice group contracted to provide services 
at a medical facility in the Phoenix-Metropolitan area.  
Participants 
Convenience sampling was used to obtain volunteer anesthesia providers, including one 
provider working at the local healthcare organization. The information gathered during the 
interview was used to determine the need for the CPG and how it can be used to affect change in 
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their practice. Four expert anesthesia providers were included in the My AGREE PLUS 
evaluation process. The CPG was tailored for the anesthesia group practicing at Mountain Vista 
Medical Center in Mesa, Arizona.  
AGREE II 
Introduction 
The Appraisal of Guidelines for Research & Evaluation (AGREE) instrument was 
originally published in 2003 as a method to determine the quality of clinical practice guidelines. 
The collaboration defined the quality of the guidelines as “the confidence that the potential 
biases of guideline development have been addressed adequately and that the recommendations 
are both internally and externally valid, and are feasible for practice.” (Brouwers et al., 2010) 
The original AGREE instrument was made up of 23 items which assessed 6 quality domains in 
the newly developed guideline. To refine the instrument, it improved the measurement properties 
to increase the reliability and validity and created a user’s manual. With this update, the 
developers updated the name to AGREE II (Brouwers et al., 2010). 
The AGREE II instrument is intended to be used by health care providers who have 
developed a guideline to be assessed before adopting the guideline in their current practice. It is 
designed to be applicable at a local level, regional level, or national level. When the tool was 
updated it also included resources such as the AGREE Research Trust which has free downloads, 
online training, references, and information about AGREE projects (Brouwers et al., 2010). 
Before beginning the appraisal process it is recommended that the user read the user’s manual in 
full. The user’s manual also states that the guideline should be appraised by a minimum of 2 
appraisers and preferably 4. This project utilized four evaluators from the anesthesia department. 
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The structure of the AGREE II evaluation includes 23 key items that are part of 6 domains (See 
Appendix A). At the end of the assessment, there are 2 global rating items that rate the overall 
guideline. The items are rated on a 7-point scale; 1 strongly disagrees and 7 strongly agrees. A 
quality score for each domain was calculated to determine a recommendation for use of the 
guideline.  
Domain 1. Scope and Purpose 
The objective of this domain is to determine if the guideline objectives are described in 
detail and are specifically related to a clinical problem associated with the specified population. 
Part 2 of this domain covers the question being answered by the guideline including the target 
population, interventions, healthcare setting, and outcomes (Brouwers et al., 2010). Part 3 
specifically addresses the population in which the guideline will be applied which may include 
the clinical description; operative patients in this study. 
Domain 2. Stakeholder Involvement 
This domain begins by determining if the developer(s) are relevant to the issue and 
involved in the development process. This may be research members or members involved in 
final recommendations. Part 2 of this domain assesses if the target population have been sought 
out and involved in the process through consultation or external review. Part 3 determines if the 
target users have clearly been defined. 
Domain 3. Rigor of Development 
The focus on the search and synthesis of the evidence is part of this domain. Terms used, 
sources, and the dates of the literature should be listed and relevant. The search strategy should 
be comprehensive and performed in a way to reduce potential bias. The criteria for selecting the 
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evidence should be listed and details of any excluded research should be clearly stated. There 
also needs to be explanations describing the methods used to develop the guideline and include 
the potential benefits, side effects, and risks that have been considered. The link between the 
research and the recommendations need to be clear and the guideline should be reviewed by 
experts that are not part of the development process. Finally, there should be a clear timeline and 
procedure for updating the guideline to include new evidence. 
Domain 4. Clarity of Presentation 
This domain ensures that the recommendation is presented in a manner that is precise and 
described the recommendations for the given population. It should also provide and compare the 
different options that are available in current practice. The last part of this domain ensures that 
the key recommendations are easily found in the guideline and they answer the main question. 
Domain 5. Applicability 
For the guideline to be effective it must be applicable to the populations targeted. This 
domain will ensure that facilitators and barriers have been considered and options to overcome 
these barriers are provided. Recommendations and tools are also provided to assist in the 
implementation such as an educational presentation. Cost and resources are discussed and 
potential impact of implementing the guideline is considered. Finally, this domain presents 
measuring recommendations to ensure the guideline is effective after implementation. 
Domain 6. Editorial Independence 
If there is any external funding or contributions, they must be clearly listed in a statement 
that explained the results have not been influenced by the external funding. If there are any 
competing interest within the developing body they must also be listed.  
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Overall Guideline Assessment 
The first question asked was to rate the overall quality of the guideline; which also uses 
the 7-point scale. The last question asked of the evaluator is if they would recommend this 
guideline for use in their current practice; the answers provided are yes, yes with modifications, 
and no. 
AGREE II PLUS 
The Agree Trust recommends that at least two experts evaluate the guideline, however, it 
is recommended there be four. When the experts are selected, they are informed to visit the 
agreetrust.org website where online training tools are made available in the form of tutorials and 
user guides. The tutorials consist of one overview tutorial that takes approximately ten minutes 
to complete and a second practice exercise tutorial that takes approximately one hour to complete 
(Agree Trust, 2018). After consent is given by the appraisers, the coordinator will send an 
invitation to the My AGREE PLUS online platform where the appraisers will gain access to the 
guideline and the evaluation tool. The coordinator will then be able to track the progress and 
results of the appraisal. Results will then be made available for this project and available to the 
appraisers.  
Intervention 
One anesthesia provider within the group was consulted to work with the author in 
developing the CPG. This consultant provided valuable information about current practice within 
the group, current equipment that is available to the group, and barriers to application of the 
CPG. Using current evidenced-based recommendations and local insight from the consultant, the 
author developed the CPG for the anesthesia group. The consultant then provided edits to the 
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CPG that would make it easier to implement at this facility. When the consultant and the author 
completed the CPG, it was then sent to the appraisers for evaluation. After the CPG was deemed 
valid for this local anesthesia group, it was presented and reviewed by the local anesthesia 
department stakeholders. The CPG was then made available to the department to adopt as the 
standard of care. (See appendix F) 
Tools 
The anesthesia providers completed online training on the use of the AGREE II 
instrument being used to evaluate the quality of the newly developed CPG. The providers 
appraised the CPG using the My AGREE PLUS on-line platform through an email invitation to 
access and evaluate the CPG.  
Data Analysis 
The My AGREE PLUS online platform provided the project investigators with results to 
the quality of the CPG. Four appraisers were identified via email to complete the appraisal 
process. The appraisers received a PDF copy of the CPG and instructions on how to complete the 
training modules and evaluation. The appraisers then answered the questions in each domain. 
Each question that the appraisers answered was rated on a 7- point scale; 1 being strongly 
disagree and 7 being strongly agree. The final scores are then calculated and given a percentage 
value based on each of the six domains. The final question stated if the appraiser would 
recommend the CPG or not. A domain score of 70% or greater was determined to be a high-
quality CPG (Brouwers et al., 2010).  
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Resources 
There was not any funding necessary for this project. There was a requirement for the 
participants’ time to use the AGREE II tool and participation in the learning and evaluation using 
the AGREE II. 
Ethical Considerations 
Respect for Persons 
This project included anesthesia providers only and not patients. Any contributions made 
were listed and consent was obtained for information and use of the evaluation tool.  
Beneficence 
There was no direct contact between this project and direct patient care. There was no 
direct risk to patients. The CPG will act as a guide to anesthesia providers to establish the safest 
standard of care for delivery to the patient. Institutional Review Board approval was obtained 
prior to implementation to ensure all parties are protected.  
Justice 
This projects target population were anesthesia providers using neuromuscular blockers 
and reversals. There were no exclusion criteria to gain access to the CPG. The newly designed 
CPG was made available to providers to adopt as a standard of care. The CPG provided the most 
up to date information about caring for patients receiving NMB drugs to reduce residual 
paralysis.  
RESULTS 
To ensure a high-quality CPG has been created using the AGREE II instrument, it needs 
to be evaluated by 2-4 appraisers who have been trained to use the My AGREE PLUS platform 
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(Brouwers et al., 2010). After consulting with an expert anesthesia provider, the CPG was 
developed for the anesthesia group. Four appraisers were then identified via email and asked to 
complete the appraisal of the CPG. The four appraisers received a PDF copy of the CPG 
(Appendix F) with instructions on how to complete the appraisal. This included instructions on 
how to create an account on My AGREE PLUS and how to complete the AGREE II Overview 
Tutorial and practice exercises to ensure complete understanding on the tool which will ensure a 
high-quality CPG is established (Brouwers et al., 2010). The author of the CPG titled “Clinical 
Practice Guideline for Monitoring Neuromuscular Blockade” sent invites to the appraisers via 
the My AGREE PLUS tool and was established as the coordinator of the group. The appraisers 
were given one month’s time to complete the appraisals, which were all completed by March 1, 
2019. Upon completion, the coordinator was emailed notification that the results were available. 
The AGREE II instrument provided in Appendix A provides the questions answered by 
the appraisers in each domain. The appraisers answered the questions using a one to seven scale 
and then had the option to add additional comments below. The domains are scored individually 
and then a final overall assessment is provided (Brouwers et al., 2010). The final question asked 
if the appraisers would recommend the CPG (Brouwers et al., 2010). The results of the 
evaluation are provided in Appendix D followed by the results comments in Appendix E. 
Each domain received a final percentage score based on the appraisers’ evaluations. 
Scores for all appraisers were added for each question (see Table 2) and displayed as a total. 
Below the totals for each question are the total for the domain which was then converted into a 
percentage score for each domain. The scores for each domain were 96% for domain 1, 92% for 
domain 2, 95% for domain 3, 94% for domain 4, 94% for domain 5, and 98% for domain 6. 
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According to Brouwers et al, a domain score above 70% represents a high-quality domain (see 
Appendix C for scoring AGREE II). The appraisers then provided the CPG with an overall 
assessment score of 100%. In the final question asking if the appraisers would recommend this 
guideline for clinical use, the appraisers all stated “yes” with no modifications.  
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TABLE 2. AGREE II score calculator. 
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TABLE 2 – Continued  
 
Each domain allows the appraiser the option to include comments on the questions 
regarding the CPG. The comments are designed to help clarify the domain and provide 
additional feedback to the coordinator of the CPG (Appendix E). While there were no comments 
on the domains of the CPG, appraiser 1 provided valuable feedback about a barrier to 
implementing the CPG stating, “the potential barrier that I can see to implementing this CPG will 
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be the cost of purchasing the new nerve stimulators since the facility does not currently have 
them. Perhaps including a cost analysis on the different monitors so they could be replaced with 
the objective monitors in the future.”  
Strengths and Weaknesses 
The CPG was developed at a local level to directly impact practice within the anesthesia 
group. The CPG included current literature from level one evidence that supports the key 
recommendation in the CPG. In the past, objective monitoring devises have been expensive and 
cumbersome to have in every anesthesia setting that uses neuromuscular blockers. Technological 
advances have made the equipment much more portable and affordable. By using the AGREE II 
appraisal tool, the author ensured that a high-quality CPG was developed and that the appraisers 
were trained to use the tool. By involving the stakeholders in the development process, they are 
more likely to implement this CPG into practice. 
One limitation identified by appraiser 1 was the potential for increased cost. Currently 
operating rooms have subjective nerve stimulators that can be used. New, objective monitors 
would need to be purchased to use objective TOF monitoring. This would be an initial cost to the 
provider or facility. While in the past this equipment was much more expensive than the 
subjective tools, it has come down to a reasonable expense when considering patient safety. It is 
recommended that as the subjective monitors need to be replaced that objective monitors take 
their place. This limitation is addressed in the CPG by stating that when objective measures are 
not available, the use of subjective measures should be mandatory.  
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DISCUSSION 
The clinical practice guideline included three key recommendations; a train of four ratio 
of 0.9 or greater should be used as the gold standard to determine if adequate recovery has taken 
place, quantitative monitoring should be available whenever a neuromuscular blocking drug is 
administered as it is more accurate at determining a TOF ratio of 0.9 or greater. If unavailable, 
the use of a subjective peripheral nerve stimulator is mandatory, and clinical signs such as 5-
second head lift or adequate tidal volume do not guarantee adequate reversal and should not be 
used alone to determine level of blockade. Based on the AGREE II evaluation performed by the 
appraisers, the CPG performed well above the 70% threshold in all domains confirming this is a 
high-quality CPG ready for implementation (Brouwers et al., 2010). All domain scored in the 
90% with the final assessment being a score of 100% that the appraisers would recommend this 
CPG for implementation. If implemented, this CPG could reduce respiratory complications 
associated with residual neuromuscular blockade in the patients receiving these drugs (Brull et 
al., 2008). Appraiser 1 identified a cost concern with purchasing new equipment. While in the 
past objective monitoring has been much more expensive, newer equipment has provided better 
accuracy with reasonable costs to the provider (Checketts M. et al., 2015).  
Conclusion 
The ability of the anesthesia provider to use neuromuscular blocking medications to assist 
in the safety of surgical procedures continues to be adapted. With recent literature stating that a 
train of four ratio of 0.9 should be the gold standard of monitoring, it’s important to accurately 
be able to identify when accurate reversal has taken place. After an extensive literature review, 
the research clearly supports the key recommendations used in the CPG. Using Lewin’s Change 
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Theory and the Knowledge to Action Framework as the theoretical framework assisted the 
author in translating the current evidence to create a CPG with the assistance of a clinical expert. 
After the development of the CPG, the author used the AGREE II appraisal tool to ensure a high-
quality guideline had been developed. Four anesthesia providers appraised the CPG giving it 
overwhelmingly positive results in the 90% and above range which is much higher than the 70% 
needed to insure a high-quality CPG (Brouwers et al., 2010). All providers stated that they would 
recommend the use of the CPG within their anesthesia group. At conclusion of the appraisal 
process the results are to be disseminated at an anesthesia convention where a poster presentation 
will be conducted. As technology becomes more affordable and advanced, the implementation of 
this CPG will become more advantageous to the stakeholders and the barriers will be reduced.  
DNP Essentials 
To complete this project, the University of Arizona DNP essentials needed to be 
achieved. DNP essential I, application of scientific underpinnings to practice, was met by the 
inclusion of Lewin’s Change Theory and the Knowledge to Action Framework that was used as 
the theoretical framework for completing this project. DNP essential II, application of 
organizational and systems leadership for quality improvement and systems thinking, was met by 
establishing an expert provider to assist in the development in the CPG followed by key 
stakeholders that appraised the CPG. DNP essential III, application of clinical scholarship and 
analytical methods for evidenced-based practice, was met by using current evidenced-based 
research to develop a clinical practice guideline. DNP essential IV, application of information 
systems/technology and patient care technology for the improvement and transformation of 
health care, was met by creating a CPG recommending the use of an objective NMB monitor that 
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can display a quantitative number that can be entered and tracked in the electronic health record. 
DNP essential V, application of healthcare policy for advocacy in health care, was met by 
creating a CPG which will improve patient outcomes by decreasing residual paralysis. DNP 
essential VI, application of inter-professional collaboration for improving patient and population 
health outcomes, was met by engaging the stakeholders who provide anesthesia to develop and 
create a CPG which will improve outcomes. DNP essential VII, application of clinical 
prevention and population health for improving the Nation’s health, was met by improving the 
anesthesia care and preventing postoperative respiratory complications. DNP essential VIII, 
application of advanced practice competencies, was met throughout the project by incorporating 
knowledge of anesthesia principles, research principles, and application of evidenced-based 
practice to develop a CPG which can be adopted at a local level to improve patient outcomes.  
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February 11, 2019 
 
Guideline Title 
 
Clinical Practice Guideline for Monitoring Neuromuscular Blockade 
 
 Guideline Objectives: 
 
This guideline provides certified registered nurse anesthetists (CRNA), physician 
anesthesiologists (MDA), and anesthesiologist assistants (AA) evidenced based guidelines for 
monitoring neuromuscular blockade after a non-depolarizing neuromuscular blocking drug is 
administered. The goal is to reduce residual paralysis in the post anesthesia care unit (PACU), 
decrease respiratory complications, and increase patient safety. This guideline provides 
evidence-based recommendations for using the proper equipment to monitor residual paralysis, 
what should be used as the gold standard to assess adequate recovery, and what methods have 
been proven to be inaccurate in determining adequate reversal.  
 
Questions: 
 
What is the most accurate way to determine if adequate reversal has taken place? What is the 
most accurate way to measure neuromuscular blockade and adequate reversal? Are current 
subjective measures accurate at determining adequate reversal? 
 
Target Population: 
 
This guideline is intended for all surgical populations that are given a neuromuscular blocking 
drug intraoperatively to assist with surgical relaxation. This includes those given non-
depolarizing and depolarizing neuromuscular blocking drugs. Surgical patients excluded from 
this guideline include those not given a neuromuscular blocking drug.  
 
Clinical Specialty:  
 
Anesthesia  
 
Intended Users: 
 
Certified Registered Nurse Anesthetists 
 
Physician Anesthesiologist 
 
Anesthesiologist Assistants 
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Key Recommendations:  
 
1. A train of four (TOF) ratio of 0.9 or greater should be used as the gold standard to 
determine if adequate recovery has taken place (2,6,10). 
 
Grade of Evidence Grade A 
Risks, Harm, Costs No risk or harm. Possible cost for new equipment if facility is not 
currently using peripheral nerve stimulators. Additional training for 
use of objective peripheral nerve stimulators.  
Benefit Adequate return of neuromuscular function for extubation and 
airway protection. Reduction in residual paralysis and adverse 
respiratory events. Decrease in costs associated with adverse 
respiratory events.  
Exclusion Patients not receiving neuromuscular blocking drug 
Level of evidence Level I 
Strength descriptor Strong recommendation 
 
 
2. Quantitative monitoring should be available whenever a neuromuscular blocking drug is 
administered as it is more accurate at determining a TOF ratio of 0.9 or greater. If 
unavailable, the use of a subjective peripheral nerve stimulator is mandatory (2,3,5,7,8,9).  
 
Grade of Evidence Grade A 
Risks, Harm, Costs No risk or harm. Possible cost for new equipment if facility is not 
currently using objective peripheral nerve stimulators. Additional 
training for use of objective peripheral nerve stimulators.  
Benefit Adequate return of neuromuscular function for extubation and 
airway protection. Reduction in residual paralysis and adverse 
respiratory events. Decrease in costs associated with adverse 
respiratory events. Accurate determination of neuromuscular 
function. 
Exclusion Patients not receiving neuromuscular blocking drug 
Level of evidence Level I 
Strength descriptor Strong recommendation 
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3. Clinical signs such as 5-second head lift or adequate tidal volume do not guarantee 
adequate reversal and should not be used alone to determine level of blockade (1,2,4,10).  
 
Grade of Evidence Grade A 
Risks, Harm, Costs No risk or harm.  
Benefit Adequate return of neuromuscular function for extubation and 
airway protection. Reduction in residual paralysis and adverse 
respiratory events. Decrease in costs associated with adverse 
respiratory events. Standardize monitoring of neuromuscular 
function 
Exclusion Patients not receiving neuromuscular blocking drug 
Level of evidence Level I 
Strength descriptor Strong recommendation 
 
 
Supporting Evidence: 
 
High quality evidence supports the use of quality measures to accurately determine the depth of 
neuromuscular blockade. Literature supports the use of an objective monitoring devise to 
accurately determine the TOF ratio. The TOF ratio should be the gold standard in determining if 
adequate reversal has taken place. Furthermore, subjective measures to determine full recovery 
from a neuromuscular blocking drug is unreliable and should not be used alone to determine 
depth of block.  
 
 
1. Cedborg, A., Sundman, E., Boden, K., Hedstrom, H., Kuylenstierna, R., Ekberg, O., & 
Erikson, L. (2014). Pharyngeal function and breathing pattern during partial 
neuromuscular block in the elderly. Anesthediology, 120, 312-325. 
2. Checketts, M., Alladi, R., Ferguson, K., Gemmell, L., Handy, J., Klein, A., . . . Pandit, J. 
(2016). Recommendations for standards of monitoring during anaesthesia and recovery 
2015: Association of anaesthestists of Great Britain and Ireland. Anaesthesia, 71(1), 85-
93. 
3. Claudius, C., & Viby-Mogensen, J. (2008). Acceleromyography for use in scientific and 
clinical practice. Anesthesiology, 108(1), 1117-1140. 
4. Debaene, B., Plaud, B., Dilly, M.-P., & Donati, F. (2003). Residual paralyis in the PACU 
after a single intubating dose of nondepolorizing muscle relaxant with an intermediate 
duration of action. American society of anesthesiologists, 98(1), 1042-1048. 
5. Drobnik, L., Sparr, H., Thorn, S.-E., Khueni-Brady, K., Rietbergen, H., Prins, M., & 
Ullman, J. (2010). A randomized simultaneous comparison of acceleromyography with a 
peripheral nerve stimulator for assessing reversal of rocuronium-induced neuromuscular 
blockade with sugammadex. European journal of anesthesiology, 27, 866-873. 
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6. Fortier, L.-P., McKeen, D., Turner, K., Warriner, B., Jones, P., Chaput, A., . . . Galarneau, 
A. (2015, August). The RECITE Study: a canadian prospective, multicenter study of the 
incendence and severity of residual neuromuscular blockade. Anesthesia analgesia, 
121(2), 366-372. 
7. Gatke, M., Viby-Mogensen, J., Rosenstock, C., Jensen, F., & Skovgaard, T. (2002). 
Postoperative muscle paralysis after rocuronium: less residual block when 
acceleromyography is used. Anaesthesiologica scandinavica, 46(1), 207-213. 
8. Murphy, G., Szokol, J., Avram, M., Greenberg, S., MAymont, J., Vender, J., . . . Gupta, D. 
(2011, November). Intraoperative acceleromyography monitoring reduces symptoms of 
muscle weakness and improves quality of recovery in the early postoperative period. . 
Anesthesiology, 115(5), 946-954. 
9. Murphy, G., Szokol, J., Marymont, J., Greenberg, S., Avram, M., Vender, J., & Nisman, 
M. (2008, September). Intraoperative acceleromyographic monitoring reduces the risk of 
residual neuromuscular blockade and adverse respiratory events in the postanesthesia 
care unit. . Anesthesiology, 109(3), 389-398. 
10. Sauer, M., Stahn, A., Soltesz, S., Noeldge-Schomburg, G., & Mencke, T. (2011, 
December). The influence of residual neuromuscular block on the incidence of critical 
respiritory events. A randomized, prospective, placebo-controlled trial. European journal 
of anaesthesiology, 28(12), 842-848. 
 
Search Methods:  
 
An extensive literature review was completed to find the best evidence to support the need for 
change. There were three primary literature searches; including PubMed, Cumulative Index of 
Nursing and Allied Health Literature (CINAHL), and the Cochrane Library. The primary 
keywords used were peripheral nerve stimulation and residual neuromuscular block. Other 
related terms included objective monitoring, neuromuscular junction, anesthesia, and subjective 
monitoring. Inclusion criteria for the literature review included studies published within the last 
ten years, human subjects, English language, and full-text availability.  
 
Strength of Evidence:  
 
The following figures were utilized to determine the strength of the evidence and the grade of 
recommendation: 
 
Level of Evidence Description 
Level I Evidence from a systematic review or meta-analysis of all relevant RCTs 
(randomized controlled trial) or evidence-based clinical practice guidelines 
based on systematic reviews of RCTs or three or more RCTs of good quality 
that have similar results 
 
Level II Evidence obtained from at least one well-designed RCT (e.g. large multi-site 
RCT). 
Level III Evidence obtained from well-designed controlled trials without randomization 
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(i.e. quasi-experimental). 
Level IV Evidence from well-designed case-control or cohort studies. 
Level V Evidence from systematic reviews of descriptive and qualitative studies (meta-
synthesis). 
 
Level VI Evidence from a single descriptive or qualitative study. 
Level VII Evidence from the opinion of authorities and/or reports of expert committees. 
Ackley, B. J., Swan, B. A., Ladwig, G., & Tucker, S. (2008). Evidence-based nursing care guidelines: Medical-
surgical interventions. (p. 7). St. Louis, MO: Mosby Elsevier. 
 
 
 
Grade Descriptor Qualifying Evidence Implications for Practice 
A Strong 
Recommendation 
Level I evidence or 
consistent findings from 
multiple studies of levels 
II, III, or IV 
Clinicians should follow strong 
recommendations unless clear or 
compelling rationale for an alternative 
approach is present.  
B Recommendation Levels II, III, or IV 
evidence and findings 
are generally consistent 
Generally, clinicians should follow a 
recommendation but should remain 
alert to new information and sensitive 
to patient preferences 
C Option Levels II, III, or IV 
evidence, but findings 
are inconsistent 
Clinicians should be flexible in their 
decision making regarding appropriate 
practice, although they may set bounds 
on alternatives; patient preferences 
should have a substantial influencing 
role 
D Option Level V evidence; little 
or no systematic 
empirical evidence 
Clinicians should consider all options 
in their decision making and be alert to 
new published evidence that clarifies 
the balance or benefit versus harm; 
patient preference should have a 
substantial influencing role 
Burns, P., Rohrich, R., & Chung, K. (2011). The Levels of Evidence and their role in Evidence-Based Medicine. 
Plastic and Reconstructive Surgery, 128(1), 305-310. 
 
Cost Analysis:  
 
A cost analysis was not performed and cost analyses were not reviewed. 
 
Method of Guideline Validation:  
 
An external review by a registered anesthesia provider who was not involved in the development 
of the clinical practice guideline and has no affiliation with the site. The guideline will undergo a 
peer review every five years to remain current with literature support, equipment, and 
recommendations.  
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Stakeholder Involvement: 
 
The Clinical Practice Guideline was developed by Austin Thruston, a student Registered Nurse 
Anesthetists from The University of Arizona. The goal of the guideline was to provide evidenced 
based guidelines for monitoring neuromuscular blockade for a local, Arizona anesthesia group. A 
local anesthesia provider assisted in gathering valuable clinical insight into the development of 
the guideline. Additional anesthesia providers evaluated and rated the guideline using the 
AGREE II guideline assessment tool to ensure a high-quality CPG. The goal of the project was 
to reduce residual paralysis and increase patient safety.  
 
Funding 
 
There was no funding required for completion of this project. The guideline was developed as a 
project by a Doctor of Nursing Practice Student.  
 
Disclaimer 
 
This guideline was developed using high quality evidence and is to be used as only a guide to 
practice. Intended users should utilize clinical judgement for each individual patient when using 
the guideline.  
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